Related Experiment Videos
[Studies on MDA and MDA/MDAa in patients with retinitis pigmentosa]
1National Ophthalmological Laboratories, China Zhongshan Ophthalmic Center, Sun Yat-den University of Medical Science, Guangzhou.
Abstract:
With fluorimetry, the concentration of malondialdehyde (MDA) and the ratio of MDA before and after the blood platelets activated (MDA/MDAa) were determined in patients with retinitis pigmentosa (RP). The results showed the above two parameters were statistically higher than those of the normal controls, which indicated the superoxidation metabolism increased and the blood was in a state of hypercoagulation in RP patients. The reasons for the results and their roles in RP disease were discussed. Treatments with anti-lipid, and anti-coagulation drugs combined with Chinese medicines were suggested.
Insights
Patients with retinitis pigmentosa (RP) show increased malondialdehyde (MDA) levels and platelet activation, indicating heightened oxidative stress and hypercoagulation. These findings suggest potential therapeutic targets for RP treatment.
Area of Science:
- Biochemistry
- Ophthalmology
- Hematology
Context:
- Retinitis pigmentosa (RP) is a group of inherited disorders that affect the retina's ability to respond to light.
- Oxidative stress and blood hypercoagulation are implicated in the pathogenesis of various diseases.
Purpose:
- To investigate malondialdehyde (MDA) levels and platelet activation in patients with retinitis pigmentosa (RP).
- To explore the relationship between oxidative stress, hypercoagulation, and RP.
Summary:
- Fluorimetry was used to measure MDA concentration and the MDA/MDAa ratio in RP patients and healthy controls.
- RP patients exhibited significantly higher MDA levels and MDA/MDAa ratios compared to controls.
- These results suggest increased superoxidation metabolism and a hypercoagulable state in RP patients.
Impact:
- The findings highlight the role of oxidative stress and hypercoagulation in RP.
- Suggests potential therapeutic strategies involving anti-lipid, anti-coagulation drugs, and traditional Chinese medicines for RP management.